Читать «Фармакотерапия в гериатрической практике. Руководство для врачей» онлайн - страница 98

American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex; American Heart Association; 2005.

Bank A. J., Kubo S. H., Rector T. S., Heifetz S. M., Williams R. E. Local forearm vasodilation with intraarterial administration of enalaprilat in humans. // Clin Pharmacol Ther. 1991; 50: 314 – 321.

Cleland J. G., Swedberg K., Follath F. [et al.]. The Euro Heart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. // Eur Heart J. 2003; 24 (5): 442 – 463.

Cleland J. G. The perindopril in elderly people with chronic heart failure (PEP–CHF) study. Hot Line I Session on XVth. World Congress of Cardiology, Barcelona, 03 September 2006.

Communal C., Singh K., Pimentel D. R., Colucci W. S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway // Circulation. – 1998; 98: 1329 – 1334.

Exercise Standards. A statement for health professionals from the American Heart Association. Special Report. // Circulation. 1990; 82 (6): 2291 – 2292.

Granger C. B., Mc Murray J. J., Yusuf S. [et al.]. Effects of candesartan in patients with chronic heart failure and reduced left. ventricular systolic function intolerant to angiotensin. converting. enzyme inhibitors: the CHARM. Alternative trial. // Lancet. 2003; 362: 772 – 776.

Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricularfunction after acute myocardial infarction // Lancet. 1994; 343: 1115 – 1122.

Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005). The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology (European Heart Journal doi: 10.1093/eurheartj/ehi205).

NSAIDS and heart failure. Review. Prescire Int. 2001; 10: 182 – 183.

Ho K. K., Anderson K. M., Kannel W. B. [et al.]. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. // Circulation. 1993; 88 (1): 107 – 115.

HFSA 2006 Comprehensive Heart Failure Practice Guideline Journal of Cardiac Failure. 2006; 12: e1–e1 22.

Mareev V., Lopatin Yu., Pervez Gh. Possible mechanisms of positive betablocker effects in the treatment of dilated cardiomyopathy // Eur. Heart. J. 1993; 14: 94.

Mac Neil J. H. Review of Sotalol safety in 3257 patients with arrhythmias after 15 June. 1991. Bristol Myers Squibb report, 1993. Data on file.

Mc Murray J. J., Ostergren J., Swedberg K. [et al.]. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic functiontaking angiotensin. Convertin genzyme inhibitors: the CHARM. Added trial. // Lancet. 2003; 362: 767 – 771.

Owan T. E., Hodge D. O., Herges R. M. [et al.]. Trends in prevalence and outcome of heart failure with preserved ejection fraction // N. Engl. J. Med. 2006; 355: 251 – 259.